Skip to main content

Table 1 Patient demographics and clinical characteristics of The Cancer Genome Atlas (TCGA) clear cell renal cell carcinoma (ccRCC) cohort (n = 463 with available RNA-Seq data), as well as our cohorts (n = 52 with available microarray data; n = 108 with available RT-PCR data) and a sunitinib-treated cohort published by Beuselinck et al. [17]a (n = 53)

From: Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma

   ccRCC TCGA
(n = 463)
ccRCC cohort 1
(n = 52)
Sunitinib treated cohorta
(n = 53)
Extended ccRCC cohort 2b
(n = 108)
   n, value % n, value % n, value % n, value %
Sex Male 297 64.15% 35 67.3% 37 69.81% 63 58.33%
  Female 166 35.85% 17 32.69% 16 30.19% 45 41.67%
Age (year) Median (range) 61 (26–90) 64 (37–90) 58 (44–80) 65 (34–90)
T T1 226 48.81% 17 32.69% NA NA 51 47.22%
  T2 59 12.74% 4 7.69% NA NA 10 9.26%
  T3 168 36.29% 31 59.62% NA NA 47 43.52%
  T4 10 2.16% 0 0.00% NA NA 0 0.00%
N N0 215 46.44% 46 88.46% NA NA 97 89.81%
  N1 15 3.24% 4 7.69% NA NA 8 7.41%
  N2 0 0.00% 2 3.85% NA NA 3 2.78%
  NX 233 50.32% 0 0.00% NA NA 0 0.00%
M M0 374 80.78% 41 78.85% NA NA 92 85.19%
  M1 76 16.41% 10 19.23% NA NA 15 13.89%
  MX 13 2.81% 1 1.92% NA NA 1 0.93%
G G1 7 1.51% 9 17.31% NA NA 24 22.22%
  G2 200 43.20% 30 57.69% NA NA 60 55.56%
  G2–G3 0 0.00% 1 1.92% NA NA 2 1.85%
  G3 183 39.52% 11 21.15% NA NA 20 18.52%
  G4 72 15.55% 1 1.92% NA NA 1 0.93%
  GX 1 0.22% 0 0.00% NA NA 0 0.00%
  NA 0 0.00% 0 0.00% NA NA 1 0.93%
Necrosis Present 218 47.08% 10 19.23% NA NA 17 15.74%
  Absent 245 52.92% 42 80.77% NA NA 91 84.26%
Follow-up time (years) Median (range) 3.1 (0.0–10.0) 3.0 (0.0–10.0) 1.0 (0.1–4.9) 3.4 (0.0–11.1)
Overall survival Deceased 152 32.83% 17 32.69% NA NA 29 26.85%
  Alive 311 67.17% 35 67.31% NA NA 79 73.15%
Cancer-specific survival Cancer-related death 104 22.46% 15 28.85% NA NA 21 19.44%
  Alive/non-cancer-related death 359 77.54% 37 71.15% NA NA 87 80.56%
Progression free survival under sunitinib therapy Yes 14 26.4%
No 39 73.6%
  1. T primary tumor, N regional lymph node, M distant metastasis present at diagnosis, G grading, NA not available
  2. accRCC cohort published by Beuselinck et al. [17]; descriptive data were not available
  3. bThis extended ccRCC cohort 2 includes the 52 patients from ccRCC cohort 1